A phase 3 pivotal study of PXL01 for the prevention of patients undergoing tendon repair surgery.
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2018
At a glance
- Drugs PXL 01 (Primary)
- Indications Post-surgical adhesions
- Focus Registrational; Therapeutic Use
- Sponsors ProMore Pharma
- 01 Feb 2018 According to a ProMore Pharma media release, this and another phase 3 trial CTP700276926 will form the basis for market authorization in the US and Canada.
- 22 Jan 2018 New trial record
- 02 Jan 2018 According to a ProMore Pharma media release, company is preparing to submit an IND to the US Food and Drug Administration in the first half of 2018.